New Two-Pronged attack on tough blood cancers
NCT ID NCT07416682
Summary
This early-stage study is testing a new type of CAR-T cell therapy designed to fight high-risk plasma cell cancers, like an aggressive form of multiple myeloma. The therapy is engineered to target two specific markers (BCMA and CD70) on cancer cells. The main goals are to check the treatment's safety, find the highest safe dose, and see if it can shrink tumors in up to 20 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.